Grau, Thomas; Selchow, Petra; Tigges, Marcel; Burri, Reto; Gitzinger, Marc; Böttger, Erik C; Fussenegger, Martin; Sander, Peter (2012). Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 56(2):1142-1145.
Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects of ethionamide, isoxyl, and thiacetazone in Mycobacterium tuberculosis strains with resistance to ETH due to inhA promoter mutations but not ethA mutations.
Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects of ethionamide, isoxyl, and thiacetazone in Mycobacterium tuberculosis strains with resistance to ETH due to inhA promoter mutations but not ethA mutations.
| Item Type: | Journal Article, refereed, original work |
|---|---|
| Communities & Collections: | 04 Faculty of Medicine > Institute of Medical Microbiology |
| Dewey Decimal Classification: | 570 Life sciences; biology
610 Medicine & health |
| Scopus Subject Areas: | Life Sciences > Pharmacology
Health Sciences > Pharmacology (medical) Health Sciences > Infectious Diseases |
| Language: | English |
| Date: | 2012 |
| Deposited On: | 03 Apr 2012 08:57 |
| Last Modified: | 07 Nov 2023 02:46 |
| Publisher: | American Society for Microbiology (ASM) |
| ISSN: | 0066-4804 |
| OA Status: | Closed |
| Publisher DOI: | https://doi.org/10.1128/AAC.05649-11 |
| PubMed ID: | 22106218 |
Grau, Thomas